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We investigated the role of daytime sleepiness and sleep quality in psychosocial outcomes of patients with obstructive sleep apnea
(OSA) treated with continuous positive airway pressure (CPAP). Thirty-seven individuals with moderate to severe OSA and
compliant with CPAP treatment for at least 3 months were compared to 27 age- and education-matched healthy controls. The
OSA group and the control group were studied with overnight polysomnography (PSG) and compared on measures of daytime
sleepiness (Epworth Sleepiness Scale), sleep quality (Pittsburg Sleep Quality Index), mood (Beck Depression Inventory, Profile of
Mood States), and functional outcomes (Functional Outcomes of Sleep Questionnaire). After CPAP treatment, the OSA group
improved on sleep quality and sleepiness. As a group, they did not differ from controls on sleep architecture after CPAP. The OSA
group also showed significant improvements in functional outcomes and was comparable to controls on mood and functional
outcomes. Persistent difficulties included lowered activity level and residual sleepiness in some individuals. Sleepiness was found to
be a significant predictor of mood and affective states, while both sleepiness and sleep quality predicted functional outcomes.These
results highlight the importance of assessment and intervention targeting psychosocial functioning and sleepiness in individuals
with OSA after treatment.
1. Introduction
Individuals with obstructive sleep apnea-hypopnea syn-
drome (OSA) experience excessive daytime sleepiness and
fatigue, decreased cognitive function and mood changes,
resulting in significant, negative consequences in work and
driving performance, and lowered quality of life (see review
by [1]). Therefore, the evaluation of OSA treatment on both
nighttime and daytime consequences of OSA is critical.
The most obvious consequence and manifestation of
untreated OSA are probably subjective sleepiness and high
propensity to fall asleep during the daytime. Engleman and
Douglas [2] reviewed 29 studies that measured sleepiness
and concluded that at least moderate impairments in terms
of excessive daytime sleepiness are indicated in patients
with OSA. Accumulating evidence suggests that the main
causes of daytime sleepiness in patients with OSA are sleep
fragmentation and sleep architecture disruptions [3]. Some
propose that sleepiness of patients with more severe OSA
may be more related to the breathing disruptions and the
associated nocturnal hypoxemia (e.g., [4]).
An association between OSA and mood disorders is
revealed by studies reporting their comorbidity (e.g., [5]).
Previous studies also showed that individuals with OSA
showed elevated scores on measures of depression, and 58%
met the DSM criteria for depression [6]. In the Wisconsin
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Sleep Cohort Study, longitudinal data demonstrated a dose-
response association between OSA and depression in a
community sample of 1408 participants [7]. On the contrary,
other studies do not find an association between OSA
and psychological problems (e.g., [8]). Authors like Cassel
contend that the so-called personality change or psycho-
logical consequence of OSA is due to a misinterpretation
of sleepiness by medical staff and the overlap of symptoms
like fatigue between OSA and depression. The implication
is that symptoms of fatigue and depression have to be
distinguished in studies investigating mood in patients with
OSA. Bardwell et al. [9] concluded from their study that
many of the previously reported links between mood and
OSA dissipate after controlling for covariates such as age,
BMI, and hypertension. But it should be noted that a strong
relationship between OSA andmood was demonstrated even
after potential confounds were controlled in a later study (see
above) [5].
The relationship between OSA and psychological prob-
lems is still uncertain, and the mechanisms of OSA-related
mood symptoms are unknown. Depressive symptoms in
patients with OSA have been proposed to be related to
oxygen desaturation and nocturnal hypoxemia (e.g., [10]) or
to sleep fragmentation and excessive daytime sleepiness [11].
It has also been shown that experimental sleep fragmentation
produces significant mood symptoms [12], supporting the
potential effects of sleep disruption and daytime sleepiness on
mood. However, it is difficult, if not impossible, for previous
studies to distinguish the more direct effects of the illness
itself (i.e., the hypoxic insults) and the indirect effects of
daytime sleepiness on mood in patients with untreated OSA.
Investigating stably treated individuals inwhich hypoxemia is
eliminated or minimized would help elucidate the remaining
effects of any persistent daytime sleepiness.
Continuous Positive Airway Pressure (CPAP) has been
reported to be effective in improving subjective and objective
measures of sleepiness in patients with OSA [13], with
therapeutic effects ranging frommoderate to large [2, 14].The
average improvement for patients with severe OSA was 4.75
points on the Epworth Sleepiness Scale (ESS, [13]). However,
it is not uncommon for individual patients to continue to
experience excessive daytime sleepinesswithCPAP treatment
(e.g., [4]). A number of authors have reported improvements
of psychological functioning afterCPAP treatment (e.g., [15]).
Several placebo-controlled studies on the reversibility of
psychopathology (mainly depression) have been conducted
with mixed results [16, 17]. Sateia [18] concluded that while
the clinical impression suggests that OSA may be directly
related to psychopathology and that treatments can reverse
the impairments, the literature does not provide unequivocal
support for these associations. In addition, another question
that is left unanswered is whether the psychosocial function-
ing of stably treated patients is comparable to their peers
without OSA.
The purpose of the current study was to investigate
the relationship between any residual sleepiness or sleep
issues and psychosocial functioning in individuals with stably
treated OSA to understand their long-term outcomes. In
order to ensure that the patients were indeed properly treated
with CPAP, data on their pre-treatment status (i.e., PSG data,
sleepiness scores, subjective sleep quality) were collected and
compared with posttreatment data. Improvements on hypox-
emia indices, sleepiness, and sleep quality were previously
reported in an earlier paper focusing on cognitive functions
[19] and will be summarized in the results section. Here, we
report in detail on how changes in sleepiness and sleep quality
relate to psychosocial functioning posttreatment. The OSA
group was also asked to rate their pre-treatment functional
outcomes retrospectively to understand if and to what extent
they perceived CPAP helped in terms of subjective daytime
functions. We then investigated the predictors of the psy-
chosocial functioning of individuals with treated OSA. Out-
come variables included the mood measures and functional
outcomes. Predictors examined were demographics, pre-
treatment disease severity, and posttreatment sleep-related
variables.
Based on the findings of previous studies, we hypothe-
sized that (1) the OSA group will show improvements in their
daytime sleepiness, sleep quality, and functional outcomes
after CPAP treatment as compared to their pre-CPAP status;
(2) current sleep variables would be more important in
predicting psychosocial outcomes in individuals with stably
treated OSA compared to pre-treatment diagnostic variables;
(3) the associations between sleepiness, sleep quality, and
psychosocial functioning would also apply to healthy age-
matched controls.
2. Methods
2.1. Participants and Procedures. Thirty-seven individuals
with OSA treated with CPAP and 27 healthy control partic-
ipants were studied. Details of the inclusion and exclusion
criteria were reported in Lau et al. [19]. Briefly, patients had
moderate to severe OSA and had been on CPAP treatment
for at least three months with compliance of at least 4
hours per night for 80% of the week; exclusion criteria
were other sleep pathologies as verified by overnight PSG
and clinical interview by attending physicians, diagnosed
psychiatric disorders (e.g., psychotic disorders, major depres-
sion with suicidal ideation), or neurological conditions (e.g.,
stroke, epilepsy), current alcohol or drug abuse, current
use of medication that could affect cognitive function (e.g.,
benzodiazepine), and undertreatment of OSA other than
CPAP. The protocol was approved by the Research Ethics
Board of the Queen Elizabeth II Health Sciences Centre and
was prepared in accordance with the Helsinki Declaration.
After the initial screening and consenting procedure, all
participants filled out questionnaires of subjective sleep
quality, sleepiness, and psychosocial measures (see below).
Then, participants completed experimental tasks of working
memory and a comprehensive neuropsychological battery
(findings reported in Lau et al. [19]). All participants also
received an overnight PSG using standardized procedures
and scoring within eight weeks of psychological testing [20].
Relevant information was extracted from patients’ medical
charts at the Sleep Clinic and Laboratory, including pre-
treatment data on PSG, daytime sleepiness, sleep quality, and
other relevant medical history and medications.
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2.2. Measures
2.2.1. Epworth Sleepiness Scale (ESS) [21, 22]. All participants
completed the ESS, a self-administered eight-item question-
naire for measuring daytime sleepiness by rating the chances
of dozing off or falling asleep in eight different situations
commonly encountered in daily life, on a scale from 0 (would
never doze) to 3 (high chance of dozing). An ESS score
> 10 (out of 24) is conventionally considered as clinically
significant [23]. ESS is a validated clinical and research tool
in assessing daytime sleepiness with high test-retest reliability
(𝑟 = 0.82) and internal consistency (Cronbach’s alpha = 0.88)
[21, 24, 25]. The reliable change index of 5.89 on the ESS
as calculated by a formula with the mean change score, the
standard deviation, and the reliability coefficient are used in
the current study to evaluate the extent of change in our OSA
group [26].
2.2.2. Pittsburgh Sleep Quality Index (PSQI). The PSQI is
a self-rated questionnaire which assesses sleep quality and
disturbances over a one-month time interval. Nineteen indi-
vidual items generate seven “component” scores including
subjective sleep quality, sleep latency, sleep duration, habitual
sleep efficiency, sleep disturbances, use of sleeping medica-
tion, and daytime dysfunction. Component scores ranging
from 0 to 3 are then summed to yield one global score (0–
21) with higher scores indicating worse sleep quality. The
global score is used to distinguish good and poor sleepers
(>5 as poor sleepers) with a diagnostic sensitivity of 89.6%
and specificity of 86.5%. Evidence of internal homogeneity
(Cronbach’s 𝛼 = 0.83) and consistency (test-retest reliability
coefficient = 0.85) was reported by Buysse et al. [27].
2.2.3. Beck Depression Inventory (BDI) [28]. On the well-
validated BDI,mild, moderate, and severe levels of depressive
symptomatology are indicated by a raw score of 14 to 19, 20 to
28, and 29 to 63, respectively.
2.2.4. Profile of Mood States (POMS) [29]. Affective states
were measured by the POMS. Participants rate their feelings
during the past week on 65 adjective scales using a 5-
point rating system from 0 (not at all) to 4 (extremely).
The profile includes a total score and scores of six affective
states: tension anxiety, depression dejection, anger hostility,
vigor activity, fatigue inertia, and confusion bewilderment.
These subscales separate out somatic symptoms (sleepiness,
fatigue) from affective symptoms (anxiety, depression), pro-
viding useful evidence to validate the potential effective-
ness of CPAP in improving mood, without the confound
of physical symptoms. The reliability and validity of the
POMS have been demonstrated in numerous studies in
a variety of normal as well as chronically ill populations
[29–31].
2.2.5. Functional Outcomes of Sleep Questionnaire (FOSQ)
[32]. The FOSQ was used to evaluate the specific impact
of excessive sleepiness or tiredness on multiple activities of
everyday living. A total score can be generated from five
factors including activity level, vigilance, intimacy, sexual
relationships, general productivity, and social outcome. The
FOSQ has been found to be capable of discriminating
between normal participants and untreated sleep apnea
patients [32]. It has very high content validity, test-retest
reliability (𝑟 = 0.91), and internal consistency (Cron-
bach’s alpha = 0.96). A total score of less than 18 is
considered as clinically significant [23]. Participants were
asked to fill out the questionnaires according to their
current condition and then their condition before using
CPAP. This is the “Then-Test” approach designed to elim-
inate treatment-induced response-shift effects and used to
provide an unconfounded indication of treatment effects
[33].
2.3. Data Analytical Strategies. Significant improvements
in PSG variables, daytime sleepiness, and subjective sleep
quality were reported in Lau et al. [19]. In the current study,
we first assessed the posttreatment changes in functional
outcomes in the OSA group using paired sample 𝑡-test.
To understand the clinical significance of the changes, the
percentages of patients and healthy controls whose scores
were in the clinical range also were compared using chi-
square analyses. Between-group independent 𝑡-tests were
used to compare the scores of the OSA group and healthy
controls on sleepiness (ESS), sleep quality (PSQI), and on
psychosocial outcomes, namely, mood (BDI, POMS) and
daytime functioning (FOSQ).
To explore the predictors of patients’ psychosocial out-
comes,moodmeasures (BDI, POMS), and subjective daytime
functioning (FOSQ) were regressed on predictors, includ-
ing age, BMI, diagnostic RDI, diagnostic minimum SpO
2
,
posttreatment sleep efficiency, current sleepiness (ESS), and
subjective sleep quality (PSQI) using stepwise regression
procedures.
Due to the number of analyses, a significance level of .01
was used for all between-group comparisons to control for
Type I error. Significance level for regression analyses was set
at .05 due to their exploratory nature.
3. Results
3.1. Participants’ Characteristics. Participants’ characteristics
and the OSA group’s clinical information were reported by
Lau et al. [19] and summarized in Table 1. Briefly, the two
groups were of comparable age and education level but as
expected, the mean BMI of the OSA group was significantly
higher than that of the control group, and the gender ratio
differed between the two groups with more males in the OSA
group and more females in the control group.
3.2. Effects of CPAP Treatment on Nighttime Sleep, Daytime
Sleepiness, and Functional Outcomes. Significant improve-
ments on respiratory and oxygen saturation indices (RDI,
minimumSpO
2
, andmean SpO
2
), sleepiness (ESS), and sleep
quality (PSQI) were reported by Lau et al. [19] and briefly
reported in Table 1.There were also significant posttreatment
improvements in functional outcomes (FOSQ), 𝑡 = 7.64 (32),
𝑃 < .000, and 𝑑 = 0.91. For measures that have established
clinical cut-offs, the percentage of individuals of the OSA
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Table 1: Participants’ characteristics and OSA group CPAP treatment information.
OSA before CPAP
(A)
(𝑛 = 37)
OSA after CPAP
(B)
(𝑛 = 37)
Controls
(C)
(𝑛 = 27)
A versus B
𝑡 (df)
B versus C
𝑡 (df)
Age (years) 57.9 (9.5)a 56.7 (10.5) 0.48 (62)
Sex (F :M) 15 : 22 19 : 8
Education (years) 15.1 (3.6) 15.7 (3.2) 0.61 (62)
Body mass index (BMI) 33.5 (7.4) 25.5 (5.0) 4.83 (62)∗∗∗
Time since diagnosis of OSA (months) 25.6 (21.1)
Duration of CPAP treatment (months) 17.8 (11.4)
Usage of CPAP per week (hours) 51.4 (6.7)
CPAP complianceb 96.1 (5.6)
Respiratory disturbance index (RDI) 42.2 (24.9) 1.7 (1.5) 4.0 (3.4) 9.52 (32)∗∗∗ 3.25 (62)∗∗
Minimum oxygen saturation (min SpO2) 80.2 (9.8) 90.3 (3.6) 88.6 (3.3) 5.61 (27)∗∗∗ 1.90 (60)
Mean oxygen saturation (mean SpO2) 93.7 (3.5) 95.7 (1.6) 95.7 (0.9) 3.17 (29)∗∗ 0.10 (62)
Epworth Sleepiness Scale (ESS) 14.4 (5.2) 8.3 (4.5) 6.6 (4.7) 7.52 (36)∗∗∗ 1.48 (62)
Pittsburg Sleep Quality Index—global score 8.5 (3.3) 4.4 (2.4) 4.6 (2.8) 5.85 (27)∗∗∗ 0.20 (62)
CPAP: continuous positive airway pressure.
aMean (SD).
bCPAP compliance is defined as percentage of days with usage >4 hours in the last 3 months. Compliance was determined objectively by downloading data
from the built-in smart card of the CPAP machines for 73% of the participants. Self-report of usage was used for the rest of the participants whose machines
were not equipped with a smart card.
∗∗P < .01, ∗∗∗P < .001.
group and that of the control group passing the thresholds
for the clinically problematic range are shown in Figure 1.
Overall, there were large reductions in the percentages of
individuals with OSA in the clinically significant range on
ESS, PSQI, and FOSQ after CPAP treatment. However, 30%
of the posttreatment OSA group still reported excessive
daytime sleepiness, twice the percentage in the healthy
control group. Also, 43% of OSA group (posttreatment) had
significant problems in functional outcomes, as compared
to 33% of the controls. These differences in the percent-
ages of clinically significant scores between the two groups
were not statistically significant using chi-square analyses,
however.
3.3. Comparisons between Treated OSA Group and Healthy
Controls on Sleep and Psychosocial Outcomes. Results of
the between-group comparisons are summarized in Table 2.
There was a trend for a difference between the two groups
in the component score of daytime dysfunction on the PSQI,
𝑡(62) = 2.14, 𝑃 = .036, with the OSA group reporting
more sleep-related daytime dysfunction than the controls
did.
No significant differences between the two groups were
detected on the twomoodmeasures, BDI and POMS. On the
BDI, 5%of patients (versus none in the control group) showed
an elevated score in the mild range (14–19). In the FOSQ, the
only difference found was on the FOSQ subscale of “activity
level,” with the OSA group having a lower activity level than
controls, 𝑡(62) = 3.00, 𝑃 < .01.
3.4. Predictors of PsychosocialOutcomes inTreatedOSAGroup
3.4.1. Emotional Functioning. BDI was predicted by post-
treatment ESS score, with sleepier patients having a higher
level of depressive symptoms (Table 3). Posttreatment ESS
also predicted POMS-total score, with worse affective states
associated with sleepiness. To delineate the affective versus
the physical components underlying mood states, individual
subscales of POMSwere regressed on the same set of variables
(Table 4). Posttreatment ESS predicted all subscales except
for vigor activity, which was predicted by PSQI, with poorer
sleep quality associated with lower vigor activity. In addition
to ESS, BMI also predicted fatigue inertia, with higher BMI
associated with worse fatigue inertia. To investigate whether
these associations apply also to the control group, post hoc
analyses on the correlations between ESS scores with BDI
and POMS were conducted. Significant correlation between
ESS and POMS was found in the control group (total score—
𝑟 = .57, 𝑃 < .01, tension anxiety—𝑟 = .40, 𝑃 < .05,
depression dejection—𝑟 = .53, 𝑃 < .01, fatigue inertia—
𝑟 = .69, 𝑃 < .001).
3.4.2. Functional Outcomes. Posttreatment FOSQ—total
score was predicted by posttreatment ESS score and post-
treatment PSQI—global score. Better functional outcomes
were associated with less sleepiness and better sleep quality
(Table 5). FOSQ—activity level was associated with lower
scores on the ESS, lower scores on the PSQI, and older age.
FOSQ—vigilance was associated with lower ESS scores.
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Table 2: Comparison between the OSA group treated with CPAP and the control group in sleep and mood questionnaires.
OSA (𝑛 = 37) Controls (𝑛 = 27) 𝑡 (df = 62) P d
Epworth sleepiness scale (ESS) 8.3 (4.5)a 6.6 (4.7) 1.48 .144 0.38
Pittsburg sleep quality index (PSQI)
Global score 4.4 (2.4) 4.6 (2.8) 0.29 .776 0.08
Subjective sleep quality 0.7 (0.6) 0.8 (0.7) 0.64 .526 0.17
Sleep latency 0.4 (0.6) 0.7 (0.6) 1.87 .066 0.50
Sleep duration 0.6 (0.8) 0.6 (0.7) 0.15 .880 0
Habitual sleep efficiency 0.3 (0.7) 0.6 (0.9) 1.38 .173 0.43
Sleep disturbances 1.2 (0.5) 1.2 (0.5) 0.47 .641 0
Use of sleep medication 0.2 (0.6) 0.1 (0.5) 0.29 .771 0.17
Daytime dysfunction 0.9 (0.7) 0.6 (0.6) 2.14 .036∗ 0.43
Beck Depression Inventory (BDI) 2.8 (4.7)a 2.9 (2.4) 0.01 .989 0.02
Profile of Mood States (POMS)
Global score 67.4 (24.0) 60.3 (18.2) 1.29 .204 0.30
Tension anxiety 6.1 (5.0) 5.0 (4.7) 0.89 .375 0.22
Depression dejection 5.0 (7.1) 5.2 (6.1) 0.11 .913 0.03
Anger hostility 4.7 (6.2) 3.7 (4.0) 0.74 .465 0.16
Vigor activity 17.5 (6.7) 19.0 (5.2) 0.96 .342 0.22
Fatigue inertia 7.4 (6.2) 4.7 (4.9) 1.89 .064 0.44
Confusion bewilderment 6.2 (4.6) 5.3 (4.5) 0.78 .436 0.20
Functional Outcomes of Sleep Questionnaire (FOSQ)
Total score 17.6 (2.2) 18.4 (1.5) 1.61 .113 0.36
Activity level 3.3 (0.6) 3.7 (0.3) 2.99 .004∗∗ 0.67
Vigilance 3.4 (0.5) 3.5 (0.5) 0.96 .341 0.20
Intimacy 3.6 (0.6) 3.8 (0.5) 1.04 .304 0.33
General productivity 3.6 (0.5) 3.8 (0.3) 1.48 .143 0.40
Social outcome 3.7 (0.5) 3.7 (0.5) 0.06 .953 0
Higher scores indicate more difficulties in all questionnaires, except for FOSQ.
aMean (SD); ∗P < .05; ∗∗P < .01.
FOSQ—intimate relationships and sexual activity, general
productivity, and social outcomes were all associated with
lower PSQI scores. These associations were not found in the
control group.
4. Discussion
This study aimed at elucidating the role of daytime sleepiness
in psychosocial outcomes of individuals with OSA treated
with CPAP. Pre- and posttreatment comparisons on subjec-
tive sleep quality (PSQI), daytime sleepiness (ESS), and func-
tional outcomes (FOSQ) revealed significant improvements,
consistent with findings of some previous studies [13, 15, 34].
4.1. Is Daytime Sleepiness an Issue in Stably Treated Individ-
uals with OSA? The percentage of individuals in the OSA
group with self-reports of pathological sleepiness dropped
from 76% to 30% after treatment, with a significant mean
change of 6.1 (c.f. the reliable change index score of 5.9
[26] and consistent with the mean reduction of 4.75 points
as reported by a comprehensive review [35]). It could be
concluded that sleepiness was significantly reduced in the
OSA group after CPAP treatment, although one-third of
individuals continued to show excessive sleepiness during
the day (compared to 15% of controls). Given that sleepiness
was found to consistently predict psychosocial outcomes in
this study, the question of what predicts residual sleepiness
in treated individuals with OSA is relevant. No significant
predictors of posttreatment ESS scores were identified in
post hoc analyses. We also investigated the potential causes
as suggested by Santamaria et al. [35], including inadequate
CPAP treatment or titration, insufficient sleep, depression,
or other sleep disorders. Issues with compliance or titration
were unlikely to be the culprit as our study participants had
good compliance and titration level was deemed suitable as
validated by PSG. In addition, mean hours of CPAP usage
were not correlated with ESS scores (𝑟 = −.259, 𝑃 = .122).
With regards to sleep restriction, ESS scores were also not
correlated with sleep duration in either the OSA group or
the control group. Other sleep pathologies were ruled out by
PSG as well. There was an association between ESS scores
and BDI scores, but it could not be concluded that the
residual sleepiness was related to depression as the mean BDI
score was well within the normal range (details discussed
below). With the lack of statistical difference in self-reported
sleepiness between the two groups, one could argue that
the sleepiness in the OSA group could just be a normal
age-related phenomenon. To investigate the potential aging
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Figure 1: Percentages of participants with OSA pre- and post-
treatment and of controls scoring in the clinically significant range
on the Epworth Sleepiness Scale (ESS), Pittsburg Sleep Quality
Index (PSQI—global score), and Functional Outcomes of Sleep
Questionnaire (FOSQ—total score).
Table 3: Prediction of psychosocial outcomes in participants with
OSA treated with CPAP using stepwise regression.
Predictors BDI POMS FOSQ
ESS (post)
𝛽 0.45 0.54 −0.42
Δ𝑅
2 .20 .29 .29
t (df) 2.59 (27) 3.33 (27) −2.67 (26)
P .015 .002 0.013
PSQI (post)
𝛽 −.37
Δ𝑅
2 0.13
t (df) −2.36 (26)
P .026
Model 𝑅2 .20 .29 .42
Adjusted 𝑅2 .17 .27 .37
F (df) 6.71 (1, 27) 11.12 (1, 27) 9.31 (2, 26)
𝑃 .015 .002 .001
Nonsignificant predictor variables including age, education, diagnostic res-
piratory disturbance index (RDI), diagnostic peripheral oxygen saturation
(SpO2), and post-treatment sleep efficiency are not shown in the table.
ESS: Epworth Sleepiness Scale; PSQI: Pittsburg Sleep Quality Index; BDI:
Beck Depression Inventory; POMS: Profile of Mood States; FOSQ: Func-
tional Outcomes of Sleep Questionnaire.
effects on sleepiness, the percentage of OSA group with an
ESS score above 2 standard deviations of the mean of the
control group was calculated. 45.9% and 5.4% of the OSA
group (pre- and posttreatment)were found to have ESS scores
above this age-corrected cut-off (16/17).These percentages are
much less than those generatedwith the original cut-off score,
which was based on a group of 72 healthy individuals in the
age range of 22 to 59 [36]. Taken together, the sleepiness as
shown in the OSA group posttreatment may not be much
more than what one may expect from a healthy person
in his/her 50s. Nevertheless, given the predictive power of
posttreatment ESS on psychosocial outcomes in the OSA
group found in this study, in addition to the rich literature
on the associations between daytime somnolence and var-
ious health variables such as high blood pressure, obesity,
coronary artery disease, and cerebrovascular disease [37, 38],
which are very common in individuals with OSA, the issue
of excessive sleepiness undoubtedly deserves more attention
in this medically vulnerable group of patients. Optimizing
treatment for individual patients whose excessive daytime
sleepiness persists with compliant CPAP usage focusing on
strategies for reducing and managing sleepiness is needed.
4.2. Are Sleep Quality, Functional Outcomes, and Psychosocial
Outcomes Problems for Stably Treated OSA Individuals? A
similar pattern of findings was shown in self-reported sleep
quality, as the proportion of poor sleepers fell from 82%
before treatment to 27% after treatment in the OSA group,
as compared to 30% in the control group. As patients and
controls did not differ on the PSQI (except for the trend for
the OSA group having worse daytime dysfunction, which
essentially taps into sleepiness), and the two groups were
mostly comparable on PSG measures, it could be concluded
that sleep quality of the OSA group was largely normalized.
No significant differences between the two groups were
detected on the two mood measures, BDI and POMS.
The percentages of people with clinical level of depressive
symptoms were also comparable between individuals with
OSA treated with CPAP and controls. These findings are in
contrast with those reported by Vernet et al. in their recent
study [4] as their healthy controls and treated OSA groups
with and without residual sleepiness had higher BDI scores
than our participants, ranging from20 to 70%having elevated
scores (adopted cut-off: >12), as compared to 0% and 8% in
our control and OSA groups, respectively. These differences
suggest that variability in psychosocial functioning across
different patient samples may be noteworthy even when
inclusion/exclusion criteria are similar. In view of the gender
ratio difference between the two groups, BDI and POMS
scores were regressed on gender in order to investigate
the potential contribution of gender on mood or symptom
reporting. Gender did not predict any mood measures (𝑃 >
.05).
There was a trend toward individuals with OSA to have
a reduced energy level even after treatment with CPAP, seen
on subscales from both the POMS and the FOSQ.Thus, indi-
viduals with OSA seemed to continue to have a compromised
level of energy and activity level after CPAP treatment.While
exercise programs implemented in patients with untreated
OSA have been found to be effective in reducing fatigue and
depressive symptoms [39], such interventions should also be
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Table 4: Prediction of Profile of Mood States subscales in participants with OSA treated with CPAP using stepwise regression.
Predictors Tension anxiety Depression dejection Anger hostility Vigor activity Fatigue inertia Confusion bewilderment
BMI
𝛽 0.38
Δ𝑅
2 .14
t (df) 3.06 (26)
P .005
ESS (post)
𝛽 0.48 0.39 0.46 0.47 0.47
Δ𝑅
2 .23 .16 .21 .27 0.22
t (df) 2.83 (27) 2.23 (27) 2.70 (27) 3.06 (26) 2.78 (27)
P .009 .035 .012 .005 .010
PSQI (post)
𝛽 −0.58
Δ𝑅
2 .33
t (df) −3.66 (27)
P .001
Model 𝑅2 .23 .15 .22 .33 .41 .22
Adjusted 𝑅2 .20 .12 .18 .31 .37 .19
F (df) 7.99 (1, 27) 4.95 (1, 27) 7.28 (1, 27) 13.39 (1, 27) 9.14 (2, 26) 7.70 (1,27)
P .009 .035 .012 .001 .001 .010
Nonsignificant predictor variables including age, education, diagnostic respiratory disturbance index (RDI), diagnostic peripheral oxygen saturation (SpO2),
and post-treatment sleep efficiency are not shown in the table.
BMI: body mass index; ESS: Epworth sleepiness scale; PSQI: Pittsburg sleep quality index.
Table 5: Prediction of Functional Outcomes of Sleep Questionnaire subscales in participants with OSA treated with CPAP using stepwise
regression.
Predictors Activity level Vigilance Intimate relationships General productivity Social outcomes
Age
𝛽 0.33
Δ𝑅
2 .12
t (df) 2.31 (25)
P .030
ESS (post)
𝛽 −0.032 −0.66
Δ𝑅
2 .09 .43
t (df) −2.12 (25) −4.52 (25) −2.30 (23)
P .044 .000 .031
PSQI (post)
𝛽 −0.43 −0.40 −0.16
Δ𝑅
2 .28 .16 0.37
t (df) −2.86 (25) −2.28 (27) −3.95 (27)
P .009 .031 .001
Model 𝑅2 .49 .43 .19 .43 .37
Adjusted 𝑅2 .43 .41 .15 .41 .34
F (df) 8.13 (3, 25) 20.41 (1, 27) 5.29 (1, 23) 20.41 (1, 27) 15.61 (1, 27)
P .001 .000 .031 .000 .001
Non-significant predictor variables including education, diagnostic respiratory disturbance index (RDI), diagnostic peripheral oxygen saturation (SpO2), and
post-treatment sleep-efficiency are not shown in the table.
ESS: Epworth sleepiness scale; PSQI: Pittsburg sleep quality index.
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considered for OSA-treated individuals with reduced energy
level.
4.3. Predictors of Psychosocial Outcomes in Treated OSA
Group. Our data showed that self-reported sleepiness was
a potent predictor of mood and functional outcomes, while
subjective sleep quality predicted functional outcomes. Age
was found to be a significant predictor of activity level, while
BMI was associated with fatigue.
4.3.1. Emotional Functioning. While themean level of depres-
sive symptoms (2.8) endorsed by patients on the BDI was well
within the minimal range (i.e., 0 to 13) and the percentage
of patients with BDI scores higher than the clinical cut-off
was only 5%, our data showed that patients’ mood was still
associated with their daytime sleepiness. Our findings did
not directly address the question regarding the association
of OSA and mood as there was no pre-treatment mood
measure. Nevertheless, the finding that mood was predicted
by sleepiness suggests a relationship between daytime sleepi-
ness associated with OSA and mood. This relationship is in
keeping with the Wisconsin Sleep Cohort Study [7], which
demonstrated a causal link between OSA and depression,
although the current study does not address the directionality
of the relationship. Significant correlations between ESS and
POMS scores in the control grouphighlight the importance of
daytime sleepiness in emotional functioning in a broad sense,
above and beyond the OSA illness.
Several studies reported a lack of correlation between
OSA and psychological functioning [40–42]. Some authors
argue that sleepiness and fatigue aremisinterpreted as depres-
sion [8], and yet others suggest that links between mood
and OSA dissipate after controlling for covariates such as
age, BMI, and hypertension in the analyses [9]. In this study,
age and BMI were not significant predictors of BDI scores,
suggesting that the association of sleepiness and mood is
independent of these factors. In regard to the argument
that sleepiness and fatigue in patients with OSA are mis-
interpreted as mood symptoms, our findings on the POMS
may offer some insight. The total score and subscale scores
separate out somatic symptoms (vigor, fatigue) from affective
symptoms (anxiety, depression). We found that sleepiness
(ESS) was associated with five of the six subscales, namely,
tension anxiety, depression dejection, anger hostility, fatigue
inertia, and confusion bewilderment, and, interestingly, not
with vigor activity. The relationships with all the affective
subscales, but not a physical scale (vigor activity), may
suggest that the mood symptoms and their associations
with sleepiness in patients with OSA are separable from the
manifestations of fatigue.
4.3.2. Functional Outcomes. Better functional outcomes were
associated with less sleepiness and better subjective sleep
quality; specifically, sleepiness predicted activity level and
vigilance, while sleep quality predicted intimate relationships
and sexual activity, general productivity, social outcome, and
activity level. These findings concur with the finding that
sleep quality is an independent predictor of daytime fatigue in
untreated OSA [43]. Taken together and consistent with the
findings on mood, current sleepiness and sleep quality play
a crucial role in daytime functioning of individuals generally
classified as “well treated.” These relationships are not found
in the healthy control group, despite the fact that the two
groups seem to have comparable sleep quality, suggesting
that the impact of the same level of quality of sleep may be
different for individuals with and without a history of OSA
and that there may be some specific factors that make an
individual with OSA more susceptible to the adverse effects
of poor sleep even after their OSA is well controlled by CPAP.
5. Conclusions
Previous studies of psychosocial functioning of individuals
with OSA usually adopt one instrument to study one aspect
of emotional functioning. We included multiple instruments
for measuring mood and functional outcomes to more fully
understand howOSA impacts the daily living of an individual
who is compliant to the standard treatment of CPAP. Predic-
tors of posttreatment psychosocial outcomes have not been
adequately studied, and this study offers some preliminary
evidence for future studies to build on; even though our
sample size was only moderate, not many predictors could
be included. Other caveats of this study were the baseline
differences between gender ratio and the BMI of the two
groups, although gender did not predict any outcomes and
BMI was only associated with fatigue.
As found in this study, daytime sleepiness and subjective
sleep quality are important predictors of functional outcomes
and mood. It is pivotal to explore specific strategies targeting
such factors [44]. For example, it would be valuable to
study how interventions like sleep hygiene education and
lifestyle management (e.g., controlling tobacco and alcohol
use, weight control) affect sleep quality and daytime sleepi-
ness and the respective impact on daytime functioning and
emotional functioning. Asmost of these interventions as well
as the CPAP usage itself involve drastic behavioral changes
and adaptations, motivational interviewing techniques could
be a valuable component in inducing and maintaining
changes in OSA patients with persistent problems in sleep
and psychosocial functioning [45].
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